The present work describes the screening and characterization of some common endocrine
disrupting chemicals for their (anti)androgenic activities. Various chemicals (mostly …

Objective— Pulmonary arterial hypertension is a progressive pulmonary vascular disorder
with high morbidity and mortality. Compelling evidence suggests that receptor tyrosine …

Background— Pulmonary arterial hypertension (PAH) is a disease of progressive vascular
remodeling, characterized by dysregulated growth of pulmonary vascular cells and …

Pulmonary arterial hypertension (PAH) is characterised by excessive pulmonary vascular
remodelling involving deregulated proliferation of cells in intima, media as well as adventitia. …

Idiopathic pulmonary fibrosis ( IPF ) is a progressive and fatal parenchymal lung disease
with limited therapeutic options, with fibroblast‐to‐myofibroblast transdifferentiation and …

Hypoxia signaling plays a major role in non-malignant and malignant hyperproliferative
diseases. Pulmonary hypertension (PH), a hypoxia-driven vascular disease, is characterized by …

Background: The ability of the right ventricle (RV) to adapt to an increased pressure afterload
determines survival in patients with pulmonary arterial hypertension. At present, there are …

Obesity is a pre-disposing condition for chronic obstructive pulmonary disease, asthma, and
pulmonary arterial hypertension. Accumulating evidence suggests that metabolic influences …

Rationale: The MSTs (mammalian Ste20-like kinases) 1/2 are members of the HIPPO
pathway that act as growth suppressors in adult proliferative diseases. Pulmonary arterial …

Pharmacological modulation of class I histone deacetylases (HDAC) has been evaluated as
a therapeutic strategy for pulmonary hypertension (PH) in experimental models of PH. …